A worldwide, exclusive partnership for the development of a therapeutic autoantibody aimed to neutralise interferon-alpha has been signed between the German biotech company ImmunoQure and the French pharmaceutical company Servier. The goal is to advance ImmunoQure’s therapeutic human Interferon-alpha autoantibody through preclinical development up to the clinical phase, that will be directly managed by Servier. The clinical target are diseases such as systemic lupus erythemathosus and Sjögren’s syndrome.